Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL
- J.F. Ascaso 1
- A. Fernández-Cruz 1
- P. González Santos 1
- A. Hernández Mijares 1
- A. Mangas Rojas 1
- J. Millán 1
- L.F. Pallardo 1
- J. Pedro-Botet 1
- F. Pérez-Jiménez 1
- G. Pía 1
- X. Pintó 1
- I. Plaza 1
- J. Rubiés-Prat 1
- 1 Foro HDL. Madrid
ISSN: 0214-9168, 1578-1879
Année de publication: 2004
Volumen: 16
Número: 6
Pages: 262-280
Type: Article
D'autres publications dans: Clínica e investigación en arteriosclerosis
Résumé
In the approach to lipid-related risk factors for cardiovascular diseases, serum high-density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the “low HDL syndrome” with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low-density lipoproteincholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. HDL-C levels of > 40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (< 100 mg/dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (> 20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome.